Q4 2025 Earnings Call February 25, 2026 8:00 AM ESTCompany ParticipantsCaryn Seidman-Becker - Chairman & CEOMichael Barkin ...
ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results